NT pro brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure:

Rada M Vucic; Vladimir Ignjatovic; Olivera  Andrejic; Katarina Cupic; Miodrag Sreckovic; Jelena Vuckovic Filipovic; Marija Sekulic; Milan Dobric; Jelena  Rakocevic

doi:10.5937/afmnai42-53487

Rada Vucic Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
Vladimir Ignjatovic Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
Olivera Andrejic Department of pulmonology, Clinical Center Kragujevac, Zmaj Jovina 30, 34000 Kragujevac, Serbia
Katarina Cupic Department of ophtalmology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
Miodrag Sreckovic Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia 2. Cardiology Clinic, University Clinical Center Kragujevac, Zmaj Jovina 30, 34000 Kragujevac, Serbia
Jelena Vuckovic Filipovic Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
Marija Sekulic Department of Higiene and Ecology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
Milan Dobric Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
Jelena Rakocevic Institute of Histology and Embryology “Aleksandar Đ. Kostić”, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia

DOI: https://doi.org/10.5937/afmnai42-53487

Keywords: prognosis, NT-proBNP, myocardial infarction

Abstract

INTRODUCTION: Many markers are used to evaluate prognosis in patients with acute myocardial infarction (AMI). Researches are focused on available markers with high sensitivity and specificity.

AIM: The aim of our study was to evaluate prognostic value of NT pro brain natriuretic peptide (NT-proBNP) and its superiority compared with other prognostic markers in patients with AMI.

PATIENTS AND METHOD: 66 patients with diagnosis AMI were enrolled in study. Evaluated variables were: symptoms, cardiovascular risk factors, laboratory (including NT-proBNP), GRACE risk score, electrocardiography, left ventricular ejection fraction (LVEF) and coronary angiography. One- and six-month major adverse cardiovascular events (MACE) included: reAMI, heart rhythm disorders, acute heart failure, stroke, fatal event.

RESULTS: Patients with one-month and six-month MACE were older, had anterior AMI, higher levels of NT-proBNP, urea, creatinine, lower LVEF, CCr and hemoglobin level. NT-proBNP is independent predictor of short-term (p=0.002) and long-term (p=0.000) prognosis. Its cut point of 1467 pg/ml is significant independent predictor of one-month MACE and cut point of 996 pg/ml is significant independent predictor of six-month MACE.

CONCLUSIONS: NT-proBNP is a strong short-term and long-term predictive marker in AMI patients without heart failure.

References

1. Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210–8.
https://doi: 10.1016/s0735-1097(01)01738-7.
2. Vucic RM, Andrejic OM, Stokanovic D, et al. Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure. Diagnostics 2023; 13(21):3348. https://doi.org/10.3390/diagnostics13213348.
3. Thygesen K, Alpert JS, Jaffe AS, ESC Scientific Document Group, Fourth universal definition of myocardial infarction. EHJ 2019; 40 (3):237–269. https://doi.org/10.1093/eurheartj/ehy462.
4. Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest 2005;65 (suppl 240):18-24.
https://doi: 10.1080/00365510500236077.
5. Heeschen C, Hamm CW, Mitrovic V, et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004 Nov 16;110(20):3206-12.
https://doi: 10.1161/01.CIR.0000147611.92021.2B.
6. O'Donoghue ML, Morrow DA, Cannon CP, et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc 2016 May 20;5(5):e002586.
https://doi: 10.1161/JAHA.115.002586.
7. Cai A, Dillon C, Hillegass WB, et al. Risk of major adverse cardiovascular events and major hemorrhage among white and Black patients undergoing percutaneous coronary intervention. J Am Heart Assoc 2019;8(22):e012874.
https://doi: 10.1161/JAHA.119.012874.
8. Tsai I-T, Wang C-P, Lu Y-C, et al. The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovasc Disord 2017;17(1):1–13.
https://doi: 10.1016/j.jval.2014.03.622.
9. Wang Y, Zhou J, Zhou P, et al. Prognostic significance of serial N-terminal pro-B-type natriuretic peptide levels in patients with acute myocardial infarction: A prospective study. Am Heart J 2023 Aug;262:90-99. https://doi: 10.1016/j.ahj.2023.04.015.
10. Nasution SA, Perkasa H, Ginanjar E, Rinaldi I. In-Hospital Major Adverse Cardiac Events Factor Predictors on ST-Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention at dr. Cipto Mangunkusumo General Hospital. eJKI. 2022;10(2):107-113. https://doi.org/10.23886/ejki.10.193.107-13.
11. Wang J, Gao W, Chen G, et al; BIPass investigators. Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes - Results from BIPass registry. Lancet Reg Health West Pac. 2022 May 30;25:100479.
https://doi: 10.1016/j.lanwpc.2022.100479.
12. Jeong JH, Lee KS, Park SM, et al. Prediction of longitudinal clinical outcomes after acute myocardial infarction using a dynamic machine learning algorithm. Front Cardiovasc Med. 2024 Apr 5;11:1340022. https://doi: 10.3389/fcvm.2024.1340022.
13. Li N, Chen R, Li J, et al. Prognostic significance of serial N-terminal pro-B-type natriuretic peptide levels in patients with acute myocardial infarction: A prospective study. Am Heart J. 2023 Aug;262:90-99.
https://doi: 10.1016/j.ahj.2023.04.015.
14. Velders MA, Wallentin L, Becker RC, et al. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 2015;169 (6):879-889.e7.
https://doi.org/10.1016/j.ahj.2015.02.019.
15. Jering KS, Claggett BL, Pfeffer MA, et al. Prognostic Importance of NT-ProBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circ. Heart Fail. 2023, 16, e010259.
https://doi: 10.1161/CIRCHEARTFAILURE.122.010259.
16. Shen S, Ye J, Wu X, Li X. Association of N-terminal pro-brain natriuretic peptide level with adverse outcomes in patients with acute myocardial infarction: A meta-analysis. Heart Lung. 2021 Nov-Dec;50(6):863-869. https://doi: 10.1016/j.hrtlng.2021.07.007.
https://doi: 10.1016/j.hrtlng.2021.07.007.
17. Sykes R, Doherty D, Morrow A, Mangion K, Rushd A, Berry C. NT-proBNP in patients presenting with myocardial infarction and non-obstructive coronary arteries without left ventricular systolic dysfunction. Am Heart J Plus. 2023 Jul 27;33:100311.
https://doi: 10.1016/j.ahjo.2023.100311.
18. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40: 437-445.
https:// doi: 10.1016/s0735-1097(02)01986-1.
19. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003; 108: 275-281.
https:// doi: 10.1161/01.CIR.0000079170.10579.DC.
20. Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B. N-terminal pro brain natriuretic peptide in relation to inflammation, myocardial necrosis and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909-1916.
https:// doi: 10.1016/j.jacc.2003.07.015.

NT pro brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure

NT-proBNP superiority for prognosis of MACE in patients with AMI without heart failure

Abstract

References